MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00223548|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : September 22, 2005
|Condition or disease||Intervention/treatment||Phase|
|Chronic Renal Insufficiency Serum Creatinine Concentration Contrast Media Exposition||Drug: sodium 2-mercaptoethane sulfonate||Phase 2|
Contrast-induced nephropathy remains a common complication of radiographic precedures. Pretreatment with Mesna (Sodium 2-mercaptoethane sulfonate) in combination with sodium chloride is more protective than sodium chloride alone in animal models of acute renal failure.
The aim of this study is therefore to determine laboratory and clinical benefit of MESNA, as an adjunct to saline hydration, in patients with known renal impairment receiving contrast media.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||106 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||MESNA Zur Prophylaxe Der Kontrastmittel-Induzierten Nephropathie|
|Study Start Date :||October 2002|
|Study Completion Date :||December 2004|
- Contrast-agent associated nephrotoxicity was defined as an increase in serum creatinine concentration >0.5 mg/dl (44 umol/l) of the baseline value 48 h after administration of the contrast media.
- Need for dialysis after the administration of contrast media.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00223548
|Division of Nephrology, University of Ulm|
|Ulm, Germany, 89081|
|Principal Investigator:||Frieder Keller, M.D.||Division of Nephrology, University Hospital Ulm|
|Principal Investigator:||Frieder Keller, M.D.||Division of Nephrology, University Hospital of Ulm|